세보플루란 시장 : 제품, 제제, 유통 채널, 용도, 최종 사용자, 지역별 분석 및 예측(-2032년)

According to Stratistics MRC, the Global Sevoflurane Market is accounted for $476.1 million in 2025 and is expected to reach $739.9 million by 2032 growing at a CAGR of 6.5% during the forecast period. Sevoflurane is a volatile, inhalational anesthetic widely used for inducing and maintaining general anesthesia. It is a colorless, non-flammable liquid with a sweet odor, making it ideal for pediatric and adult patients. Known for its rapid onset and recovery, sevoflurane provides smooth induction with minimal airway irritation. It has a low blood-gas partition coefficient, allowing quick adjustments in anesthesia depth. While generally well-tolerated, it can cause dose-dependent hypotension and rare nephrotoxicity.

According to the World Journal of Surgery published in 2021, 3646 operations were conducted to satisfy the surgical requirements of the population in India.

Market Dynamics:

Driver:

Increasing Surgical Procedures

The growing number of surgical procedures worldwide is propelling considerable growth in the sevoflurane market. Sevoflurane is a popular inhalation anesthetic that is used in hospitals and ambulatory surgery centers due to its quick induction and recovery times. Demand is also being increased by the growing incidence of chronic illnesses, improvements in less invasive surgery, and the development of a larger healthcare system. Sevoflurane's vital function in contemporary anesthetic methods is further supported by the market's expansion due to the aging population's increased need for surgical procedures.

Restraint:

High Cost Compared to Alternatives

The high cost of sevoflurane compared to alternative anesthetics significantly hinders its market growth. Healthcare facilities, especially in cost-sensitive regions, may opt for lower-cost substitutes like isoflurane or desflurane, limiting sevoflurane adoption. This cost barrier affects procurement decisions, particularly in developing markets, reducing its overall demand. Additionally, price-conscious hospitals and clinics may restrict its usage, impacting sales and revenue growth for manufacturers.

Opportunity:

Advancements in Anesthesia Technology

Advancements in anesthesia technology are driving significant growth in the market, enhancing patient safety, precision, and efficiency in surgeries. Innovations such as automated anesthesia delivery, real-time monitoring, and low-flow techniques optimize Sevoflurane usage, reducing wastage and side effects. The rise of minimally invasive procedures and improved vaporizers further boost demand. Additionally, enhanced pharmacokinetics and better recovery profiles make Sevoflurane the preferred choice for anesthetists. These advancements collectively fuel market expansion, ensuring safer and more effective anesthesia administration worldwide.

Threat:

Potential Adverse Effects

The Sevoflurane market faces potential adverse effects due to regulatory restrictions, supply chain disruptions, and health concerns. Stringent environmental regulations on volatile anesthetics hinder market expansion. Supply chain volatility, including shortages of raw materials, affects production and pricing. Additionally, concerns over neurotoxicity in pediatric and elderly patients raise safety issues, leading to reduced adoption. Rising competition from alternative anesthetics and increasing preference for total intravenous anesthesia (TIVA) further restrict market growth and profitability.

Covid-19 Impact:

The COVID-19 pandemic had a mixed impact on the sevoflurane market. While elective surgeries declined due to lockdowns, the demand for Sevoflurane surged in critical care settings, particularly for ventilated COVID-19 patients. Supply chain disruptions and hospital resource reallocation initially slowed market growth, but post-pandemic recovery, increased surgical procedures, and improved healthcare infrastructure have driven a strong resurgence in demand across the industry.

The hospitals segment is expected to be the largest during the forecast period

The hospitals segment is expected to account for the largest market share during the forecast period as these facilities are primary users of the anesthetic for surgical procedures. With rising surgical volumes, increasing healthcare infrastructure, and advancements in anesthesia techniques, hospitals are boosting demand for Sevoflurane. Additionally, the growing prevalence of chronic diseases requiring surgical interventions further fuels market growth. The segment benefits from strong adoption due to its effectiveness, safety profile, and widespread use in general anesthesia, reinforcing its positive impact on market expansion.

The high purity sevoflurane segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the high purity sevoflurane segment is predicted to witness the highest growth rate due to its superior efficacy, safety, and reduced side effects in anesthesia applications. With increasing surgical procedures and rising demand for minimally invasive treatments, hospitals and clinics are prioritizing high-purity formulations for better patient outcomes. Additionally, stringent regulatory standards and advancements in pharmaceutical manufacturing are ensuring consistent quality, further boosting market adoption.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share due to an increase in surgical operations, technological developments in anesthetic, and growing healthcare expenditures. Sevoflurane is the recommended option for inhalation anesthetic because to its effectiveness, quick recovery period, and few side effects. Demand is also fueled by an aging population and the rising incidence of chronic diseases. Its popularity is further aided by continuous research and development in anesthetic administration technologies. This market expansion adds to the region's cutting-edge healthcare infrastructure and guarantees better patient results.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR because of an increase in surgical operations, a growing healthcare infrastructure, and technological breakthroughs in anesthetic. By offering safer and more effective inhalation anesthetic, the market is improving patient outcomes. Demand is further fueled by an aging population, growing medical tourism, and hospital development. Sevoflurane is a major factor in raising surgical effectiveness and general healthcare standards in the area, and government programs to improve healthcare accessibility also support market growth.

Key players in the market

Some of the key players in Sevoflurane Market include AbbVie Inc., Accord Healthcare, AstraZeneca, Baxter International Inc., Beijing Zizhu Pharmaceutical Co., Ltd., Endo International plc, Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Hospira Inc., Jiangsu Hengrui Pharmaceuticals Co., Ltd., Lunan Pharmaceutical Group Co., Ltd., Maruishi Pharmaceutical Co., Ltd., Merck KGaA, Piramal Critical Care, Shandong Keyuan Pharmaceutical Co., Ltd., Shanghai Huayuan Ethylene Co., Ltd. and Troikaa Pharmaceuticals Ltd.

Key Developments:

In March 2025, AstraZeneca and Alteogen Inc. have entered into an exclusive license agreement for ALT-B4, a novel hyaluronidase utilising Hybrozyme(TM) platform technology. Under the terms of the agreement, AstraZeneca will acquire worldwide rights to use ALT-B4 to develop and commercialise subcutaneous formulations of several oncology assets.

In February 2024, AstraZeneca has entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing next-generation radioconjugates (RCs). The acquisition marks a major step forward in AstraZeneca delivering on its ambition to transform cancer treatment and outcomes for patients by replacing traditional regimens like chemotherapy and radiotherapy with more targeted treatments.

Products Covered:

• Generic Sevoflurane
• Branded Sevoflurane

Formulations Covered:

• Standard Purity Sevoflurane
• High Purity Sevoflurane

Distribution Channels Covered:

• Direct Sales
• Distributors/Wholesalers
• Online Pharmacies
• Retail Pharmacies

Applications Covered:

• Induction of Anesthesia
• Maintenance of Anesthesia

End Users Covered:

• Hospitals
• Ambulatory Surgical Centers (ASCs)
• Specialty Clinics
• Other Healthcare Facilities

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 Application Analysis
• 3.8 End User Analysis
• 3.9 Emerging Markets
• 3.10 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Sevoflurane Market, By Product

• 5.1 Introduction
• 5.2 Generic Sevoflurane
• 5.3 Branded Sevoflurane

6 Global Sevoflurane Market, By Formulation

• 6.1 Introduction
• 6.2 Standard Purity Sevoflurane
• 6.3 High Purity Sevoflurane

7 Global Sevoflurane Market, By Distribution Channel

• 7.1 Introduction
• 7.2 Direct Sales
• 7.3 Distributors/Wholesalers
• 7.4 Online Pharmacies
• 7.5 Retail Pharmacies

8 Global Sevoflurane Market, By Application

• 8.1 Introduction
• 8.2 Induction of Anesthesia
• 8.3 Maintenance of Anesthesia

9 Global Sevoflurane Market, By End User

• 9.1 Introduction
• 9.2 Hospitals
• 9.3 Ambulatory Surgical Centers (ASCs)
• 9.4 Specialty Clinics
• 9.5 Other Healthcare Facilities

10 Global Sevoflurane Market, By Geography

• 10.1 Introduction
• 10.2 North America
  • 10.2.1 US
  • 10.2.2 Canada
  • 10.2.3 Mexico
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 Italy
  • 10.3.4 France
  • 10.3.5 Spain
  • 10.3.6 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 New Zealand
  • 10.4.6 South Korea
  • 10.4.7 Rest of Asia Pacific
• 10.5 South America
  • 10.5.1 Argentina
  • 10.5.2 Brazil
  • 10.5.3 Chile
  • 10.5.4 Rest of South America
• 10.6 Middle East & Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 UAE
  • 10.6.3 Qatar
  • 10.6.4 South Africa
  • 10.6.5 Rest of Middle East & Africa

11 Key Developments

• 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 11.2 Acquisitions & Mergers
• 11.3 New Product Launch
• 11.4 Expansions
• 11.5 Other Key Strategies

12 Company Profiling

• 12.1 AbbVie Inc.
• 12.2 Accord Healthcare
• 12.3 AstraZeneca
• 12.4 Baxter International Inc.
• 12.5 Beijing Zizhu Pharmaceutical Co., Ltd.
• 12.6 Endo International plc
• 12.7 Fresenius Kabi AG
• 12.8 Hikma Pharmaceuticals PLC
• 12.9 Hospira Inc.
• 12.10 Jiangsu Hengrui Pharmaceuticals Co., Ltd.
• 12.11 Lunan Pharmaceutical Group Co., Ltd.
• 12.12 Maruishi Pharmaceutical Co., Ltd.
• 12.13 Merck KGaA
• 12.14 Piramal Critical Care
• 12.15 Shandong Keyuan Pharmaceutical Co., Ltd.
• 12.16 Shanghai Huayuan Ethylene Co., Ltd.
• 12.17 Troikaa Pharmaceuticals Ltd. .